38225-32-0

Usage

Uses

Used in Organic Synthesis:
Lithium isopropylamide is used as a strong base for the deprotonation of acidic protons to form carbon nucleophiles, which is crucial in the synthesis of a wide range of organic compounds.
Used in Pharmaceutical Industry:
Lithium isopropylamide is used as a reagent in the preparation of pharmaceuticals, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
Lithium isopropylamide is used as a key intermediate in the synthesis of agrochemicals, such as pesticides and herbicides, to improve agricultural productivity and crop protection.
Used in Specialty Chemicals Industry:
Lithium isopropylamide is used as a building block in the production of specialty chemicals, which are essential for various industrial applications, including materials science, coatings, and adhesives.

Upstream product

• 75-31-0 isopropylamine 

Downstream Products

• 70557-55-0 4-Isopropyl-3,3,5,5-tetramethyl-1,2-diphenyl-[1,2,4,3,5]triazadisilolidine 
• 68728-91-6 N-tert-Butyl-N'-isopropyl-Si-methyl-Si-phenyl-silanediamine 
• 65768-28-7 N-(Fluormethylphenylsilyl)-isopropylamin 
• 65768-29-8 N-(Fluordiphenylsilyl)-isopropylamin 
• 128924-99-2 N-isopropyl-2-phenylquinolin-4-amine 
• 128925-04-2 N,N'-Diisopropyl-2-[1-phenyl-eth-(E)-ylideneamino]-benzamidine 
• 381209-09-2 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid 
• 128897-27-8 1-(4-methoxyphenyl)-3,3-dimethyl-4-phenyl-2-azetidinone 
• 14757-78-9 3-bromofurfural 
• 129161-77-9 2,4,6-tri-t-butylphenyl-fluoro-isopropylaminoborane 
• 31036-96-1 diphenylphosphino isopropylamine 

Relevant academic research and scientific papers

Metal precursor compound including imido group

Provided is a substrate having excellent reactivity with a substrate. Are a metal precursor compound capable of forming a metal thin film having a low impurity content in a wide temperature range, and a method for depositing a metal film using the same. The metal precursor compound for deposition of the metal layer is represented by Chemical Formula 1. , Chemical Formula 2. , Chemical Formula 3. (Wherein R M is a metal selected from the group consisting of Si, Ge and Sn, and is R a metal selected from the group consisting of compounds represented by. 1 Chem. R. 2 And R3 N is independently hydrogen or a C 1 to 5 hydrocarbon group, X and is hydrogen. 1 Is each independently a halogen element.

Efficient chromium-based catalysts for ethylene tri-/tetramerization switched by silicon-bridged/N,P-based ancillary ligands: A structural, catalytic and DFT study

High performance catalysts switched by a series of silicon-bridged/N,P-based ancillary ligands have been explored. The precatalyst supported by L1 possessed a large steric bulk and exhibited a high activity of 16.8 × 106 g (mol Cr)-1 h-1 as well as a total selectivity of 99% toward 1-hexene and 1-octene. The selectivity for 1-hexene was adjustable from 59% to 88%. The catalyst bearing an L2 ligand, facilitated by a smaller steric bulk, displayed an identical activity of 13.0 × 106 g (mol Cr)-1 h-1 and a superior selectivity of 75% towards 1-octene under the appropriate conditions. The DFT calculations elucidated the reason for these excellent and tunable activities and selectivities.

PHARMACEUTICAL COMPOUNDS

The invention provides a compound of the formula (I) or a salt, solvate, tautomer or N-oxide thereof for use in the treatment or prophylaxis of a disease state or condition mediated by protein kinase A and/or protein kinase B, wherein the ring Q is a benzene ring; J2-J1 is N=CR7 or R1aN-CO; G is OH or NR5R6; E is CONR7, NR7CO, C(R8)=C(R8) or (X)m(CR8R8a)n where X is O, S or NR7; provided that when J2-J1 is R1aN-CO, E is other than NR7CO; m and n are each 0 or 1, where m + n = 1 or 2; A is a bond and R4 and R4a are absent, or A is a saturated optionally substituted C1-7 hydrocarbon linker group having a maximum chain length of 5 atoms extending between E and G, one carbon atom in the linker group A being optionally replaced by O or N; R1,Rla, R2, and R3 are each H; halogen; C1-6 hydrocarbyl optionally substituted by halogen, OH or C1-2 alkoxy; CN; CONHR8; NH2; NHCOR10 or NHCONHR10; R4 is H or C1-4 alkyl; R4a is H, C1-4 alkyl or a group R9; R5 and R6 are each selected from H, R9 and C1-4 hydrocarbyl optionally substituted by halogen, C1-2 alkoxy or R9;or NR5R6 forms a saturated 4-7 membered monocyclic heterocyclic group; R7 is H or C1-4 alkyl; R8 and R8a each H or saturated C1-4 hydrocarbyl optionally substituted by fluorine; R9is a monocyclic or bicyclic carbocyclic or heterocyclic group containing up to 3 ring heteroatoms selected from N, O and S; or R4, R4a and A together form a saturated monocyclic 4-7 membered heterocycle; or NR5R6, R4 and A form a saturated 4-7 membered monocyclic heterocycle; or R4,together with R7 or R8 and A and E form a 4-7 membered saturated monocyclic heterocycle; or NR5R6 and R7 or R8 together with A and E form a 4-7 membered saturated monocyclic heterocycle; and R10 is optionally substituted phenyl or benzyl.

Pharmaceutically active cyclohexyl compounds and their preparation

The chemical compounds of the invention are useful as the active compound in drugs because of their anticonvulsant and/or antianoxic activity. They have the general formula STR1 wherein Z is a hydroxyl group; a group--OM wherein M is an alkali metal atom or an equivalent atom fraction of an alkaline-earth metal or an amino group such as --NH2, and R is a linear or branched alkyl group containing from 1 to 9 carbon atoms, and optionally substituted by one or more halogen atoms; a linear or branched alkenyl or alkynyl, alkoxyalkyl, or acylalkyl group containing from 2 to 9 carbon atoms and optionally substituted by one or more halogen atoms; an aryl or arylalkyl or aryloxyalkyl group comprising at least one aromatic radical and an alkyl chain having from 1 to 4 carbon atoms.